5AM Venture Management, LLC reported 16 positions worth $287.89M for the quarter ended Jun 30, 2026, down 13.9% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 2. Its largest holding is MapLight Therapeutics, Inc. at 11.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
No new positions this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | MPLT MapLight Therapeutics, Inc. | Healthcare | 950.0K | $34.05M | 11.83% | 0 | 0.0% | Unchanged | 2.09% |
| 2 | TYRA Tyra Biosciences, Inc. | Healthcare | 1.03M | $32.88M | 11.42% | 0 | 0.0% | Unchanged | 1.56% |
| 3 | TRDA Entrada Therapeutics, Inc. | Healthcare | 4.06M | $29.85M | 10.37% | 0 | 0.0% | Unchanged | 9.61% |
| 4 | PHVS Pharvaris N.V. | Healthcare | 797.6K | $27.58M | 9.58% | 0 | 0.0% | Unchanged | 1.35% |
| 5 | CAMP Camp4 Therapeutics Corp | Healthcare | 5.87M | $25.65M | 8.91% | 0 | 0.0% | Unchanged | 10.13% |
| 6 | ARTV Artiva Biotherapeutics, Inc. | Healthcare | 2.35M | $22.83M | 7.93% | 0 | 0.0% | Unchanged | 4.81% |
| 7 | TECX Tectonic Therapeutic, Inc. | Healthcare | 606.7K | $20.85M | 7.24% | 0 | 0.0% | Unchanged | 3.15% |
| 8 | ZNTL Zentalis Pharmaceuticals, Inc. | Healthcare | 3.95M | $19.15M | 6.65% | 0 | 0.0% | Unchanged | 5.51% |
| 9 | CLDX Celldex Therapeutics, Inc. | Healthcare | 497.3K | $18.50M | 6.43% | 0 | 0.0% | Unchanged | 0.63% |
| 10 | EYPT EyePoint, Inc. | Healthcare | 1.05M | $15.02M | 5.22% | 0 | 0.0% | Unchanged | 1.21% |
| 11 | BHVN Biohaven Ltd. | Healthcare | 739.0K | $11.00M | 3.82% | 0 | 0.0% | Unchanged | 0.49% |
| 12 | SRZN Surrozen, Inc. | Healthcare | 271.3K | $7.04M | 2.44% | -116.3K | -30.0% | Reduced | 2.33% |
| 13 | SKYE Skye Bioscience, Inc. | Healthcare | 1.21M | $6.71M | 2.33% | 0 | 0.0% | Unchanged | 24.39% |
| 14 | ALXO Alx Oncology Holdings Inc | Healthcare | 3.06M | $6.33M | 2.2% | 0 | 0.0% | Unchanged | 2.21% |
| 15 | TARA Protara Therapeutics, Inc. | Healthcare | 1.37M | $5.23M | 1.82% | 0 | 0.0% | Unchanged | 2.25% |
Tip. Select a row to see that position’s full history at 5AM Venture Management.
As of its Q2 2026 13F filing, 5AM Venture Management, LLC’s five largest positions were MapLight Therapeutics, Inc. (MPLT) at 11.8%, Tyra Biosciences, Inc. (TYRA) at 11.4%, Entrada Therapeutics, Inc. (TRDA) at 10.4%, Pharvaris N.V. (PHVS) at 9.6%, Camp4 Therapeutics Corp (CAMP) at 8.9% of the reported portfolio.
5AM Venture Management, LLC reported a 13F portfolio worth $287.89M across 16 positions for Q2 2026. That is down 13.9% from the previous quarter.
Its largest sales by value were Erasca, Inc. ($56.40M), GH Research PLC ($8.05M), Surrozen, Inc. ($3.02M). It exited 2 positions entirely.
From the Form 13F-HR reports 5AM Venture Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.